SUPPLEMENTARY FILES

SUPPLEMENTARY TABLE 1 Characteristics of the training and validation datasets

	Training dataset (n = 984)	Validation dataset (n = 299)
	n (%) or median (IQR)	n (%) or median (IQR)
OncotypeDX recurrence score	16 (12–21)	15 (10–21)
OncotypeDX recurrence score category		
Low (< 18)	572 (58.1%)	179 (59.9%)
Intermediate (18–30)	338 (34.3%)	99 (33.1%)
High (> 30)	74 (7.5%)	21 (7.0%)
Age (years)	57.7 (49.0–64.9)	58.0 (49.6–67.2)
Tumor size (mm)	11 (8–16) (16 missing)	11 (8–16)
ER status	95 (90–98) (69 missing)	95 (90–99)
PR status	80 (30–90) (69 missing)	80 (40–95)
HER2 IHC result > 0	633 (69.2%) (69 missing)	210 (70.2%)
Histologic grade		
1	103 (11.4%)	39 (13.3%)
2	322 (35.6%)	87 (29.7%)
3	479 (53.0%)	167 (57.0%)
Missing	80	6
Nuclear grade		
1	66 (8.1%)	16 (5.4%)
2	593 (72.6%)	229 (76.6%)
3	158 (19.3%)	54 (18.1%)
Missing	167	0

Abbreviations: ER, estrogen receptor; PR, progesterone receptor